CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWARK, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees between August 14, 2023 and August 28, 2023 in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualified stock options to purchase an aggregate of 270,000 shares of CymaBay common stock as inducements material to the employees entering into employment with CymaBay in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grants. These stock option grants had exercise prices of $12.07, $12.40 and $13.81 per share, respectively, which were equal to the closing price of CymaBay’s common stock on the applicable grant dates for the stock options. The stock options will vest and become exercisable as to 25% of the underlying shares on the first anniversary of their respective grant date, and will vest and become exercisable as to the remaining 75% of the underlying shares in 36 equal monthly installments from the first anniversary of their respective grant date, subject to the applicable employee’s continued employment with CymaBay on such vesting dates. About CymaBayCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin. Public Relations Contact: Theresa DolgeEvoke Kyne(609) [email protected] Investor Relations Contact: Hans VitzthumLifeSci Advisors, LLC(617) [email protected]